CTS Corp Q2 Sales Edge Up 1.1%, Net Income Dips 3.6%
Ticker: CTS · Form: 10-Q · Filed: Jul 24, 2025 · CIK: 26058
| Field | Detail |
|---|---|
| Company | Cts Corp (CTS) |
| Form Type | 10-Q |
| Filed Date | Jul 24, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Electronic Components, Industrial Sensors, Medical Devices, Q2 Earnings, Foreign Exchange Risk, Manufacturing, Net Income Decline
Related Tickers: CTS
TL;DR
**CTS is treading water with slight sales growth but a net income dip, so don't expect a breakout performance.**
AI Summary
CTS Corp reported a net sales increase of 1.1% to $150.2 million for the second quarter of 2025, up from $148.6 million in the prior-year quarter. For the six months ended June 30, 2025, net sales were $298.8 million, a slight decrease from $299.0 million in the same period of 2024. Net income for the second quarter of 2025 was $18.5 million, or $0.58 per diluted share, compared to $19.2 million, or $0.60 per diluted share, in the second quarter of 2024, representing a 3.6% decline. The company's strategic outlook includes continued investment in advanced materials and components, with a focus on the industrial and medical markets. Risks include fluctuations in foreign currency exchange rates, which impacted sales by $0.8 million in the second quarter of 2025. The company also incurred $0.5 million in building and equipment relocation costs during the first six months of 2025. Despite these challenges, CTS Corp maintains a strong balance sheet with total assets of $900.5 million as of June 30, 2025.
Why It Matters
CTS Corp's modest sales growth and slight net income dip signal a challenging but stable environment for investors, suggesting that while the company is not experiencing rapid expansion, it is maintaining its market position. For employees, the continued investment in advanced materials indicates job stability and potential for innovation within the company. Customers can expect continued product development, particularly in industrial and medical sectors, which could lead to more advanced solutions. In the broader market, CTS's performance reflects the current demand for electronic components and sensors, highlighting the competitive pressures and the importance of strategic investments in high-growth areas.
Risk Assessment
Risk Level: medium — The risk level is medium due to the slight decline in net income by 3.6% to $18.5 million in Q2 2025 compared to Q2 2024, and the impact of foreign currency exchange rates, which reduced sales by $0.8 million. Additionally, the company incurred $0.5 million in building and equipment relocation costs, indicating ongoing operational adjustments that could affect profitability.
Analyst Insight
Investors should hold CTS stock, monitoring future reports for sustained revenue growth and improved net income margins. Focus on the company's strategic investments in industrial and medical markets, as these segments could drive future profitability and offset currency headwinds.
Financial Highlights
- revenue
- $150.2M
- total Assets
- $900.5M
- net Income
- $18.5M
- eps
- $0.58
- revenue Growth
- +1.1%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Industrial | ||
| Medical |
Key Numbers
- $150.2M — Q2 2025 Net Sales (Increased by 1.1% from Q2 2024)
- $18.5M — Q2 2025 Net Income (Decreased by 3.6% from Q2 2024)
- $0.58 — Q2 2025 Diluted EPS (Decreased from $0.60 in Q2 2024)
- 1.1% — Q2 2025 Net Sales Growth (Year-over-year increase)
- 3.6% — Q2 2025 Net Income Decline (Year-over-year decrease)
- $0.8M — Foreign Currency Impact (Negative impact on Q2 2025 sales)
- $0.5M — Relocation Costs (Incurred in the first six months of 2025)
- $900.5M — Total Assets (As of June 30, 2025)
Key Players & Entities
- CTS CORP (company) — filer of the 10-Q
- $150.2 million (dollar_amount) — net sales for Q2 2025
- $148.6 million (dollar_amount) — net sales for Q2 2024
- $18.5 million (dollar_amount) — net income for Q2 2025
- $19.2 million (dollar_amount) — net income for Q2 2024
- $0.58 (dollar_amount) — diluted EPS for Q2 2025
- $0.60 (dollar_amount) — diluted EPS for Q2 2024
- $0.8 million (dollar_amount) — negative impact from foreign currency exchange rates on Q2 2025 sales
- $0.5 million (dollar_amount) — building and equipment relocation costs for the first six months of 2025
- $900.5 million (dollar_amount) — total assets as of June 30, 2025
FAQ
What were CTS Corp's net sales for the second quarter of 2025?
CTS Corp's net sales for the second quarter of 2025 were $150.2 million, representing a 1.1% increase from $148.6 million in the second quarter of 2024.
How did CTS Corp's net income change in Q2 2025 compared to Q2 2024?
CTS Corp's net income decreased by 3.6% to $18.5 million in Q2 2025, down from $19.2 million in Q2 2024.
What was the diluted earnings per share for CTS Corp in Q2 2025?
The diluted earnings per share for CTS Corp in Q2 2025 was $0.58, a decrease from $0.60 per diluted share in Q2 2024.
What impact did foreign currency exchange rates have on CTS Corp's sales in Q2 2025?
Foreign currency exchange rates had a negative impact of $0.8 million on CTS Corp's sales in the second quarter of 2025.
What were CTS Corp's total assets as of June 30, 2025?
As of June 30, 2025, CTS Corp reported total assets of $900.5 million.
Did CTS Corp incur any significant one-time costs in the first half of 2025?
Yes, CTS Corp incurred $0.5 million in building and equipment relocation costs during the first six months of 2025.
What are CTS Corp's key strategic focus areas mentioned in the filing?
CTS Corp's strategic outlook includes continued investment in advanced materials and components, with a particular focus on the industrial and medical markets.
How does CTS Corp's Q2 2025 performance compare to the first six months of 2024?
For the six months ended June 30, 2025, net sales were $298.8 million, a slight decrease from $299.0 million in the same period of 2024.
What is the overall sentiment regarding CTS Corp's Q2 2025 filing?
The sentiment is mixed, with modest sales growth offset by a decline in net income and ongoing operational costs like relocation expenses and foreign currency impacts.
What should investors consider regarding CTS Corp's future performance?
Investors should consider CTS Corp's ability to translate strategic investments in industrial and medical markets into sustained revenue growth and improved net income, while managing foreign currency fluctuations and operational costs.
Risk Factors
- Foreign Currency Fluctuations [medium — financial]: Fluctuations in foreign currency exchange rates negatively impacted sales by $0.8 million in the second quarter of 2025. This indicates a sensitivity to global economic conditions and currency movements, which can affect reported revenues.
- Relocation Costs [low — operational]: The company incurred $0.5 million in building and equipment relocation costs during the first six months of 2025. These one-time expenses can temporarily depress profitability and operational efficiency.
Industry Context
CTS Corp operates in the electronic components manufacturing sector, specifically focusing on printed circuit boards. The industry is characterized by rapid technological advancements, global supply chain complexities, and demand driven by sectors like automotive, industrial, and medical. Competition is often intense, requiring continuous innovation and cost management.
Regulatory Implications
As a manufacturer of electronic components, CTS Corp is subject to various regulations related to product safety, environmental standards, and international trade. Compliance with these regulations is crucial to avoid penalties and maintain market access. Changes in trade policies or tariffs could also impact its global operations and profitability.
What Investors Should Do
- Monitor the impact of strategic investments in advanced materials and components.
- Assess the ongoing impact of foreign currency fluctuations.
- Analyze the normalization of earnings after one-time relocation costs.
Glossary
- Diluted EPS
- Earnings per share calculated by dividing net income by the total number of diluted shares outstanding. It represents the earnings attributable to each share of common stock, assuming all convertible securities and stock options were exercised. (Key metric for profitability per share, showing a slight decrease to $0.58 in Q2 2025.)
- Foreign Currency Impact
- The effect of changes in exchange rates on the value of a company's financial transactions and reported results when operating in multiple currencies. (Negatively impacted Q2 2025 sales by $0.8 million, highlighting a financial risk.)
- Building and Equipment Relocation
- Costs associated with moving physical assets, such as buildings and machinery, from one location to another. (Incurred $0.5 million in the first six months of 2025, impacting short-term profitability.)
Year-Over-Year Comparison
Compared to the prior year, CTS Corp reported a modest 1.1% increase in net sales for Q2 2025 to $150.2 million, but net income saw a 3.6% decline to $18.5 million, resulting in lower diluted EPS of $0.58. While total assets remain strong at $900.5 million, the company faced headwinds from $0.8 million in negative foreign currency impact and $0.5 million in relocation costs during the first six months of 2025, which may have contributed to the margin compression.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 24, 2025 regarding CTS CORP (CTS).